Philogen

Philogen is a clinical-stage, publicly traded biotech leveraging antibody-based targeting to deliver therapeutics to diseased tissues, aiming to improve efficacy and reduce systemic toxicity. The company has built a proprietary pipeline of clinical-stage products, primarily in oncology, and operates as an integrated entity with research conducted through its Swiss subsidiary, Philochem. Led by its scientific founder, Prof. Dario Neri, Philogen combines strong academic roots in protein engineering with industrial drug development capabilities. Its strategy focuses on advancing its late-stage candidates while expanding its platform technology.

Antibody-based targeted delivery platforms, including antibody-cytokine fusions (immunocytokines), for concentrating bioactive agents (cytokines, small molecules) at disease sites.

Operates in the highly competitive immuno-oncology space, competing with large pharma and biotech companies developing checkpoint inhibitors, ADCs, cell therapies, and other cytokine therapies. Its differentiation lies in its specific antibody-targeting technology designed to localize potent immune stimulants to the tumor microenvironment.